Elevance Health — formerly Anthem, Inc., rebranded in 2022 — is a vertically integrated American health insurer and health services company. Its core proposition is aggregating risk from individuals, employers, and government programs, collecting premiums, and paying medical claims on behalf of those members. It then attempts to capture additional margin by delivering ancillary services — pharmacy, behavioral health, care management, data analytics — through its Carelon subsidiary.
Elevance serves approximately 104 million consumers through its insurance plans and services businesses. It holds exclusive Blue Cross Blue Shield licenses in 14 states, giving it a protected geographic franchise in large markets including California (Anthem), New York, Georgia, Virginia, and Indiana. The Blue brand is arguably one of the most trusted marks in American healthcare.
| Segment | Q1 2026 Revenue | Growth YoY | Key Dynamics |
|---|---|---|---|
| Health Benefits | $42.5B | +2.6% | Core insurance; premium yields up but membership declining in MA & Medicaid |
| Carelon (CarelonRx + Services) | $18.0B | +7.9% | PBM + health services; fastest-growing segment; ~$71.7B FY 2025 revenue |
| Corporate & Other | Small/eliminations | — | Includes CMS accrual; drag on GAAP earnings |
| Total Operating Revenue | $49.5B | +1.5% | FY 2025: $197.6B |
Insurance premiums are highly recurring — members typically auto-enroll annually and medical coverage is a near-necessity. Employer group contracts are multi-year and sticky, though Medicare Advantage and Medicaid are subject to annual government rate-setting and enrollment churn. CarelonRx pharmacy revenues are contractual but depend on maintaining plan formulary positioning. Overall revenue quality is high, but the margin on that revenue is acutely sensitive to medical cost trends — making earnings far more volatile than revenue.
Elevance has demonstrated meaningful pricing power in commercial and ACA individual markets — Q1 2026 results showed revenue growth driven by "higher premium yields" even as membership declined. However, in government programs (Medicare Advantage, Medicaid), pricing is determined by regulators, not the market. This creates a structural ceiling: Elevance can respond to cost trends by raising premiums in commercial lines, but is largely a price-taker in government programs, which represent roughly half its membership.
Revenue has grown from approximately $121B (FY 2021) to $197.6B (FY 2025), a five-year CAGR of roughly 10%. The stock's 5-year total return is a sobering −13.7%, reflecting the market's reassessment of margins relative to that top-line growth.
The headline story of 2025 and 2026 is margin compression. Elevance's Benefit Expense Ratio — the key profitability metric for insurers — hit 90.0% for full-year 2025 (vs. 88.5% in 2024), with Q4 2025 spiking to a troubling 93.5%. Q1 2026 came in at 86.8%, modestly better than feared. GAAP operating margin fell from roughly 6.5% a year ago to 4.2% in Q1 2026 — partly distorted by the $935M CMS accrual and $129M in restructuring charges. Adjusted operating margins are meaningfully higher. The FY 2025 adjusted EPS was $30.29; the 2026 guide of at least $26.75 represents a significant year-over-year step-down, confirming that 2026 is genuinely a trough year.
Free cash flow in FY 2025 was approximately $3.2 billion, a 30% decline from the prior year — partly due to the Blue Cross Blue Shield antitrust settlement payment. However, Q1 2026 operating cash flow surged to $4.3 billion (vs. $1.0B in Q1 2025), and management is guiding for full-year 2026 operating cash flow of at least $5.5 billion. This is a critical figure: cash generation remains robust even in a trough earnings year. The company has maintained operating cash flow well above net income in most periods, which is a positive quality signal.
| Metric | Value | Assessment |
|---|---|---|
| Total Long-Term Debt | ~$30.8B | Has risen from ~$25B in 2023 |
| Cash & Short-Term Investments | ~$36.2B | Exceeds total debt — net cash positive on a gross investment basis |
| Net Debt / EBITDA | ~2.3× | Manageable; annual interest ~$670M well covered |
| Debt-to-Equity | 72.8% | Up from 61.4% five years ago; leverage creeping higher |
| Interest Coverage (EBIT/Interest) | ~5.9× | Comfortable |
| CMS Accrual Liability (Q1 2026) | $935M | Range: −$585M to +$565M from accrued; tail risk exists |
The balance sheet also carries operating lease obligations and pension liabilities. Debt maturity risk is manageable but investors should note that leverage has risen over the past three years as Elevance financed acquisitions and buybacks, even as earnings compressed.
Insurance is a structurally negative working capital business in the best sense — premiums are collected before claims are paid, creating a permanent float. Elevance's capital expenditures are modest (property and equipment purchases were $196M in Q1 2025), making this a relatively capital-light model. Growth investment flows primarily through acquisitions and IT/digital infrastructure, not hard assets.
This is where the picture becomes more nuanced. Elevance's five-year average ROIC was approximately 26.5% — genuinely exceptional. However, ROIC has declined significantly in 2024–2025 due to margin compression and rising debt. Current trailing ROIC is closer to 6–7%, well below the historical average and arguably below a reasonable cost of capital when adjusted risk is considered. The key question is whether this represents cyclical trough or structural impairment.
Boudreaux, President and CEO since November 2017 (tenure: ~8.3 years), is one of the most experienced executives in managed care. Her background is operational — she ran UnitedHealth Group's United Healthcare insurance division before joining Elevance, making her ideally suited to manage a complex multi-line insurer. She successfully shepherded the company through the 2022 Anthem → Elevance Health rebranding and oversaw the scaling of Carelon into a major standalone services platform.
Her tenure track record is mixed. Revenue nearly doubled under her watch. The Carelon transformation is strategically sound. However, the stock's 5-year return of −13.7% reflects the market's punishment for margin failures in government programs — some of which were industry-wide, some of which reflect execution gaps specific to ELV (the CMS risk-adjustment data issue, in particular, is a reputational and financial blemish that raises governance questions).
Skin in the game: Boudreaux owns approximately 0.059% of outstanding shares, worth roughly $45–50 million at current prices — meaningful but not founder-level alignment. Total compensation of $20.47M (92% in equity/bonuses) is above the US market median for a company of this size, though arguably appropriate given the complexity of the role. No significant open-market purchases by insiders in the past 12 months are evident from the record.
Mark Kaye (CFO, EVP) has expanded his remit in February 2026 to also oversee Carelon following the departure of Carelon President Peter Haytaian. This dual role is either a sign of confidence in Kaye or a gap in Carelon leadership depth — the jury is out. Kaye has been credible in financial communication, providing unusually specific guidance during a volatile period.
Felicia Norwood (EVP, Chief Health Benefits Officer) now leads the consolidated Health Benefits organization. Her background in government programs is specifically relevant given that Medicaid and Medicare Advantage are the key battlegrounds for the next 24 months.
The March 2026 leadership reshuffles — bringing in Aimée Dailey to lead government programs and Kristy Duffey (ex-Optum) as President of Carelon Health — suggest management is bringing in talent with specific operational depth in exactly the areas causing pain. This is a constructive signal.
The Board is predominantly independent, which is standard for a company of this scale. Boudreaux is President and CEO but not Chairman. Board tenure averages 12.5 years — experienced but arguably at risk of insularity. No activist investor presence has been disclosed. The CMS data reporting failure raises legitimate questions about internal controls and compliance culture that the Board should be held accountable for.
Elevance has been a consistent and aggressive capital returner: $4.1 billion returned to shareholders in 2025 alone, and $1.5 billion in Q1 2026. The company has repurchased over $53.79 billion in shares cumulatively — reducing share count from ~260M to ~221M, a 15% reduction. Dividend has been raised consistently. M&A has been largely bolt-on and strategically coherent (Carelon acquisitions). The one concern: buybacks were executed at high prices in 2023–2024 when the stock was $450–540, meaning capital was deployed at valuations that look expensive in retrospect.
Elevance's moat is real but narrow in certain dimensions. There are three identifiable moat components:
This is the crown jewel. Elevance holds exclusive BCBS licenses in 14 states. No competitor can sell Blue-branded products in those markets. The Blue brand carries decades of trust with employers, HR departments, and beneficiaries. Employer groups — particularly large self-insured employers — have a strong preference for Blue-branded plans due to the breadth of the provider network and administrative continuity. This geographic exclusivity functions as a quasi-regulatory moat. It is also why Elevance's commercial book is more durable than its government book during regulatory disruption.
With 45+ million medical members and ~104 million total consumer relationships, Elevance negotiates provider contracts from a position of immense leverage. Hospitals and physicians in most markets have no credible alternative to being in the Blue network. This scale also enables investment in proprietary clinical data, predictive analytics (HealthOS platform), and AI-driven care management tools that smaller insurers cannot replicate economically.
Carelon — which reached $71.7B in revenue in 2025 — represents an attempt to build a UnitedHealth/Optum-style services moat. By insourcing pharmacy (CarelonRx), behavioral health, care management, home health, and data analytics, Elevance captures additional margin that would otherwise flow to third-party vendors. This moat is building, not yet fully established. Carelon's external revenue (services sold to non-Elevance plans) is growing but remains a small fraction of total Carelon revenue.
Verdict: Narrow-to-Medium moat, stable to slightly eroding in government segments. The BCBS brand is genuinely durable. The Carelon vertical integration thesis is compelling but unproven at scale. Government program profitability has no moat — rates are set by CMS and state agencies, and Elevance is a price-taker in Medicare Advantage and Medicaid.
The moat shows up clearly in the commercial book's stability and employer retention rates. It does not protect against Medicare/Medicaid policy risk, which is the dominant investor concern in 2026.
The managed care industry is undergoing a structural reset driven by three simultaneous forces: post-pandemic medical cost normalization (utilization rebounding sharply), a government reimbursement squeeze (CMS proposed a near-flat 0.09% average rate increase for 2027 Medicare Advantage plans — effectively a real-terms cut in a 7–10% medical inflation environment), and major federal policy disruption via the One Big Beautiful Bill Act, signed July 4, 2025.
The OBBBA mandates nearly $1 trillion in Medicaid cuts over a decade, implements work requirements for Medicaid beneficiaries, tightens ACA enrollment windows, eliminates automatic re-enrollment, and removes the enhanced premium subsidies that drove record ACA marketplace enrollment. This is not merely a cyclical headwind — it is a structural reshaping of government-sponsored insurance markets.
| Competitor | Key Exposure | 2025–2026 Status | Relative to ELV |
|---|---|---|---|
| UnitedHealth Group (UNH) | MA, Commercial, Optum | Severe: MCR 88.9% FY25; first revenue decline since 1989; −19% single-day drop Jan 2026 | ELV better positioned in commercial; both face MA pressure |
| Humana (HUM) | Almost pure-play MA | Crisis-level: massive Q4 2025 net loss; Star Ratings cliff; market exits | ELV far more diversified; Humana is the sector's most damaged peer |
| CVS Health / Aetna (CVS) | MA, Commercial, PBM | Aetna MCR 94.8% Q4 2025; barely breaking even on insurance | ELV's Carelon vs. CVS's Caremark is the key PBM battle |
| Cigna (CI) | Commercial, Evernorth PBM | Relatively stable; sold MA business; Evernorth growing | ELV's primary commercial benchmark; Cigna shows what focus on commercial looks like |
The sector-wide selloff has been indiscriminate, but on examination, Elevance is meaningfully better-positioned than Humana or CVS/Aetna. It has more diversified revenue streams and a credible path to margin recovery. UnitedHealth remains the gold standard for vertical integration, though its current crisis is stunning for a company of its historical quality.
The U.S. population is ageing irreversibly. The 65+ demographic cohort grows by approximately 10,000 per day. Government-sponsored health coverage (Medicare, Medicaid) will expand in absolute enrollee numbers over the next decade regardless of rate policy. The complexity of healthcare — chronic disease management, behavioral health, specialty pharmacy — creates perpetual demand for coordinated care services that companies like Elevance are positioned to supply.
The ACA marketplace restructuring from the OBBBA will reduce enrollment meaningfully. Medicaid disenrollment from work requirements will shrink managed Medicaid populations. Government fiscal pressure on MA reimbursement appears to be a multi-year structural reality, not a temporary anomaly. AI-driven healthcare navigation tools could, over time, reduce the administrative value-add insurers provide — a 5–10 year disruption risk, not imminent.
| Metric | Current | 5yr Historical Avg | Assessment |
|---|---|---|---|
| Trailing P/E (GAAP) | 16.7× | ~17–19× | Roughly fair on GAAP; distorted by CMS accrual |
| Forward P/E (adj. $26.75 guide) | ~14.9× | ~17× | Below historical average; discount justified but not extreme |
| P/E on 2027 (≥12% growth off $25.75) | ~13.3× | ~17× | Compelling if 2027 recovery materialises |
| EV/EBITDA | ~9× | ~12–14× | Materially discounted; screams value on this metric |
| FCF Yield (on $5.5B+ OCF guide) | ~6.3% | ~4–5% | Attractive; cash generation supports the thesis |
| Dividend Yield | 1.7% | ~1.2–1.5% | Above historical average; dividend well-covered |
| Price-to-Book | ~2.0× | ~3–4× | Significant compression from peak |
ELV is down approximately 30% from its peak of ~$540 (2024–2025 highs). The decline reflects: (1) a broad managed care derating as the MA rate environment deteriorated; (2) ELV-specific Medicaid margin compression; (3) the CMS risk-adjustment notice and $935M accrual, which raised governance and compliance concerns; (4) the OBBBA policy shock reducing long-term ACA and Medicaid growth expectations; and (5) a sharp step-down in earnings guidance from $30+ adj. EPS in 2025 to $26.75 in 2026.
The stock has recovered from its 52-week low of $273.71 (August 2025) to ~$399, representing a ~46% recovery that followed Q1 2026 results, the final CMS 2027 MA rate revision (better than the initial 0.09% proposal), and analyst upgrades from BofA and others.
Using conservative assumptions: FY2026 operating cash flow of $5.5B, 3% terminal growth in operating cash (below 10-year revenue CAGR of ~10%), 10.5% discount rate, and $22.5B net debt adjustment: implied enterprise value is approximately $85–95B, implying per-share intrinsic value of roughly $375–430. At $400, the stock appears roughly fairly valued on a conservative DCF — meaning the entire upside depends on the 2027 recovery thesis proving out and multiples re-rating.
The critical question. The OBBBA's Medicaid cuts are structural and permanent, not cyclical. ACA enrollment headwinds are structural. MA reimbursement pressure appears to be a multi-year feature, not a bug. These are genuine fundamental impairments, not merely temporary. However, Elevance is not a value trap if: (a) Carelon grows into a meaningfully higher-margin business over 3–5 years, (b) commercial book pricing power holds, and (c) management successfully exits loss-making government program geographies and reprices the remaining book. The honest answer is that this is not clearly a value trap, but the margin of safety at $400 is slim. A pullback toward $320–340 would offer a substantially more compelling entry.
Dividends: Elevance pays a quarterly dividend of $1.72/share ($6.88 annualised), yielding approximately 1.7% at current prices. The dividend has been consistently raised, representing a credible return to shareholders. FCF coverage is comfortable given the $5.5B+ operating cash flow guide.
Share Buybacks: The company repurchased 3.7 million shares for $1.1 billion in Q1 2026 at a weighted average price of $304.68 — an excellent use of capital at that entry point, well below current prices. The Board has ~$5.6B of repurchase authority remaining. Cumulatively, the company has repurchased over $53.79 billion in shares, reducing the share count by roughly 15% over the past several years. The concern: significant buybacks executed at $450–540 in 2023–2024 represent capital allocated suboptimally in retrospect.
M&A: Acquisitions have been largely coherent — CareBridge (home health), behavioral health platforms, and data analytics capabilities to build out Carelon. No empire-building disasters are apparent. The strategic logic of vertical integration mirrors UnitedHealth/Optum, which has proven to be value-creative over a decade.
Reinvestment into Organic Growth: The OpenAI partnership, investment in the Sydney Health digital platform, and AI-driven care management represent genuine technology investment. Management cited an improving adjusted operating expense ratio (down 20 bps to 10.5% in Q1 2026), partly attributed to AI-driven efficiency gains. R&D spending is embedded in operating costs rather than separately reported, but Carelon's rapid growth reflects ongoing reinvestment.
Stated strategic priorities for 2026–2027: Management has declared 2026 a "Year of Execution" with four pillars: (1) aggressive portfolio repositioning in MA and Medicaid (exiting loss-making markets, repricing, tightening benefits); (2) cost discipline and AI-driven operational efficiency; (3) scaling Carelon externally beyond captive Elevance members; and (4) restoring credibility with CMS by resolving the risk-adjustment data issue by July 31, 2026.
Credibility on guidance: ELV's guidance record has been imperfect — the company cut 2025 guidance twice as medical cost trends came in worse than expected. The Q1 2026 earnings beat (adj. EPS of $12.58 vs. $10.74–$10.80 consensus) and subsequent guidance raise are positive signals but one quarter does not a track record make. The 2027 promise of "at least 12% adjusted EPS growth" off a revised $25.75 baseline implies adj. EPS of at least ~$28.85 — credible if Medicaid rates normalise and MA margins recover to guided levels.
(1) CMS Risk-Adjustment Resolution (by July 31, 2026): Resolving the data submission inquiry — and avoiding threatened sanctions such as enrollment halts — would remove a significant overhang. A final payment near or below the $935M accrual would be a catalyst.
(2) 2027 Final MA Rate Rule: Already better than the initial 0.09% proposal. CMS ultimately revised rates closer to ~5% when accounting for coding and population adjustments. A continued improvement in 2028 rates would re-rate the sector.
(3) Medicaid Rate Normalisation in 2027: If state Medicaid agencies adjust rates to reflect actual acuity of the post-redetermination population, Medicaid margins could recover from the guided negative 1.75% in 2026 toward the targeted 2–4% range. This is the most important swing factor for 2027 earnings.
(4) Carelon External Revenue Scaling: Any announcement of Carelon winning material external contracts (health systems, government agencies, other payers) would serve as evidence that the services business can grow beyond its captive base — a significant re-rating catalyst.
Elevance has pursued concrete, if not fully quantified, AI deployment. The company has an enterprise partnership with OpenAI for generative AI capabilities embedded across operations. The adjusted operating expense ratio improved 20 basis points year-over-year to 10.5% in Q1 2026 — management partially attributed this to AI-driven automation in clinical review, claims processing, and member navigation. The Sydney Health app uses AI to personalise care recommendations. The HealthOS platform enables real-time clinical data exchange and analytics for care management decisions.
Carelon Insights — the data analytics arm — is explicitly being positioned as an AI-driven business that can sell predictive analytics and payment integrity solutions to health systems and other payers. This is potentially high-margin and capital-light, but remains nascent.
The long-term structural threat from AI to health insurers is real but non-imminent. AI could theoretically reduce the information asymmetry that currently allows insurers to underwrite profitably (better disease prediction could lead to adverse selection if patients use AI to optimise plan choices). AI-driven navigation tools could reduce member reliance on insurer-provided care management. Regulatory and liability frameworks make this a 7–10 year horizon risk, not a 2–3 year concern.
Elevance possesses claims, clinical, pharmacy, and behavioral health data on over 100 million Americans — one of the most comprehensive longitudinal health datasets in the private sector. This is an asset of increasing value in an AI-enabled healthcare world. The question is whether Elevance can monetise this proprietary dataset via Carelon Insights, or whether regulatory constraints (privacy, HIPAA) limit commercialisation. Early evidence suggests modest but real progress.
Insider Ownership: CEO Boudreaux owns ~0.059% of shares worth ~$45–50M. Total insider ownership is typical for a large-cap company of this scale — low in percentage terms, but non-trivial in dollar value. No meaningful open-market buying by insiders is apparent in the trailing 12 months, which is a neutral-to-negative signal in a stock that has corrected significantly from highs.
Institutional Sentiment: Baupost Group (a value-oriented deep-value fund led by Seth Klarman) holds ELV as its fourth-largest position, having trimmed 4% of its stake in Q4 2025 but maintaining a significant position. Baupost's continued presence is a meaningful signal of long-term fundamental conviction. Multiple analyst upgrades have come through in April–May 2026 following the Q1 earnings beat — BofA upgraded to Buy citing a Medicaid margins trough, Wolfe Research and Wells Fargo also in the bullish camp.
Analyst Consensus: 17 analysts cover ELV with a consensus rating of Buy. Average price target: approximately $386–$387 — slightly below current prices of ~$400, suggesting the recent rally has caught up to consensus. Bull case target: $485–$507. Bear case: $297. The wide spread reflects genuine uncertainty about the 2027 recovery timeline.
Short Interest: No unusually elevated short interest signals are evident. The stock is not heavily shorted, which reduces the potential for a short-squeeze-driven rally but also means there is no significant forced-buy tailwind.
The OBBBA's ~$1 trillion in Medicaid cuts, work requirements, and ACA enrollment restrictions are permanent structural headwinds — not cyclical. If Medicaid rolls shrink materially (estimates suggest 10–15M people could lose coverage), Elevance's Medicaid premium revenue base contracts permanently. There is no regulatory cycle that reverses this without a change in federal government. This is the single most underappreciated long-term structural risk. State Medicaid rate adjustments may never fully compensate for higher acuity populations and reduced membership.
The $935M CMS accrual may prove insufficient — management acknowledges the liability could be up to $565M higher. Worse, if CMS imposes sanctions (enrollment halts in Medicare Advantage plans), ELV's ability to write new MA business could be impaired for years. The July 31, 2026 deadline is a live risk event. Beyond this specific matter, the broader MA reimbursement environment remains hostile: a near-zero rate increase in a high medical inflation environment structurally compresses margins.
The bull case is entirely predicated on 2026 being the trough. If medical cost trends in Medicaid, MA, and ACA plans remain elevated through 2027 (underlying Medicaid cost trend remains "at the high end of mid-single-digit"), the recovery is deferred. Each year of delay compresses intrinsic value. With benefit expense ratios at 86.8% in Q1 2026 (vs. a target of ~90.2% for the full year, implying meaningful H2 deterioration is baked in), there is limited room for error. A single quarter where costs overshoot will revive investor fears and re-test the $273 lows.
The departure of Carelon President Peter Haytaian and CFO Kaye's expanded dual role creates real execution risk in Carelon's most critical period. Carelon's external revenue growth thesis — turning an internal cost center into a revenue-generating services business — has never been tested at scale. UnitedHealth's Optum took nearly a decade to reach its current profitability. If Carelon stalls or fails to generate the margin uplift management promises, the valuation case deteriorates significantly.
Elevance holds a significant investment portfolio (~$36B in cash and investments). In a declining rate environment, investment income — which contributed ~$1/share of the Q1 2026 beat — will compress. Separately, ~$30.8B in long-term debt means rising rates increase refinancing costs. The company's leverage has risen (D/E from 61.4% to 72.8% over 5 years) at a time when earnings are under pressure — a potentially uncomfortable combination if credit markets tighten.
$230–$260 per share. Assumes: 2027 medical cost trends remain elevated (no recovery), Medicaid margins remain negative through 2027, CMS sanctions are imposed limiting new MA enrollment, and OBBBA-driven enrollment losses exceed expectations. At $240, ELV would trade at approximately 9× a severely impaired adj. EPS of ~$26.75 with multiple compression justified by regulatory risk. This scenario requires several simultaneous negative outcomes and is not the base case — but is plausible under a worst-case policy and cost environment.
At $400, the upside in the bull case is ~$160 (40%). The downside in the bear case is ~$140–170 (35–43%). The risk/reward ratio is approximately 1:1 to 1.1:1 — not the 2:1 or better asymmetry that characterises an ideal entry. The margin of safety is insufficient at current prices for an aggressive position. At $320–$340, the math shifts materially: upside to $520 is ~55–60%, downside to $240 is ~25–30%, yielding a much more attractive 2:1 ratio. This is the basis for the "Buy on Weakness" verdict rather than an outright Buy today.
Elevance Health is a fundamentally sound business navigating one of the most challenging regulatory and medical cost environments in managed care's recent history. The BCBS brand franchise, Carelon vertical integration strategy, and robust cash generation (~$5.5B+ guided OCF for 2026 even in a trough year) are genuine strengths. The 2027 recovery thesis — at least 12% adjusted EPS growth — is credible if Medicaid rate normalisation occurs and the CMS matter is resolved without sanctions.
However, at ~$400, the stock has already recovered 46% from its August 2025 lows and sits near consensus analyst price targets. The risk/reward asymmetry is insufficient to justify a full position. Multiple structural headwinds — the OBBBA Medicaid cuts, MA reimbursement compression, and the unresolved CMS liability — introduce real tail risks that are not fully compensated at current prices. Insider buying has been absent, and the earnings guidance trajectory requires flawless execution in complex government program markets where Elevance has shown vulnerability.
This is a stock to own, but at the right price. The thesis is sound; the entry point is not quite right today.